International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

NCT02065765 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Metastatic Gastric Cancer
Metastatic Adenocarcinoma of the Gastroesophageal Junction

Interventions

BIOLOGICAL: Ramucirumab

Sponsor

Eli Lilly and Company